Akèy › Myozit
Etid klinik pou Myozit ap rekrite nan Etazini
20 etid pou Myozit ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Durham, NC10 etid
- Boston, MA6 etid
- New York City, NY6 etid
- Chicago, IL6 etid
- Houston, TX5 etid
- Miami, FL4 etid
- Cedar Rapids, IA4 etid
- Phoenix, AZ3 etid
- Plantation, FL3 etid
- Jacksonville, FL3 etid
- Los Angeles, CA3 etid
- Pittsburgh, PA3 etid
- Gainesville, FL3 etid
- Orange, CA3 etid
- Dallas, TX3 etid
- Ann Arbor, MI3 etid
- Charlotte, NC3 etid
- Washington, DC3 etid
- Baltimore, MD3 etid
Pa eta
- Alabama3 etid
- Arizona4 etid
- Florid7 etid
- Georgia3 etid
- Illinois7 etid
- Iowa4 etid
- Kalifòni11 etid
- Kansas3 etid
- Maryland6 etid
- Massachusetts6 etid
- Michigan3 etid
- Minnesota4 etid
- New York7 etid
- North Carolina12 etid
- Pennsylvania4 etid
- Tennessee3 etid
- Texas7 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Environmental Risk Factors for the Anti-synthetase Syndrome
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT01276470Adult and Juvenile Myositis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 100 · Tout sèks · Mizajou Sep 24, 2026 · NCT00017914RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Ap rekriteFaz 2/3
Laj 6 a 75 · Tout sèks · Mizajou Sep 17, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07103746Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07823101A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT05895786A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Sep 15, 2026 · NCT06916806A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 74 · Tout sèks · Mizajou Sep 10, 2026 · NCT07085104FT839 in Autoimmune Diseases
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Sep 2, 2026 · NCT07800871A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Aug 28, 2026 · NCT06925542Descartes-08 in Autoantibody Myositis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07391605A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 7, 2026 · NCT06733935AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT06991114A Study of AZD0120 in Autoimmune Diseases
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07295847A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 14, 2026 · NCT07115745A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Apr 27, 2026 · NCT07160205Muscle Health Measurements Using Electrical Impedance Myography
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 a 89 · Tout sèks · Mizajou Apr 3, 2026 · NCT07502989MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Ap rekriteEtid obsèvasyon
Laj 7 ak plis · Tout sèks · Mizajou Jan 28, 2026 · NCT07374107Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Ap rekriteFaz 1 bonè
Laj 45 a 75 · Tout sèks · Mizajou Jan 16, 2026 · NCT06479863Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.